BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsReiterationPrice Target
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.